Emile R. Mohler, MD, principal investigator of CLEVER, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial.

ORLANDO, Fla.—CLEVER, a late-breaking clinical trial presented at this year’s American Heart Association (AHA) scientific sessions, found that for patients with peripheral artery disease (PAD), supervised exercise and stenting showed equivalent improvement in walking distance compared with optimal medical care, with the supervised exercise group arm walking the farthest at six months. Study investigator Emile R, Mohler, III, MD explained the results and implications to Cardiovascular Business.

Mohler and his colleagues were surprised by the achievement of longer pain free walking distance on a treadmill by the supervised exercise group compared with the stent arm. However, the stent group had the most improvement in quality of life measures.

This video was conducted collaboratively with ClinicalTrialResults.org.